UnitedHealth faces three big questions before stock can recover, Bank of America says

Bank of America analysts have maintained a 'Neutral' rating on UnitedHealth Group (UNH), despite a new Berkshire Hathaway investment, citing three critical uncertainties that could prolong stock underperformance. Key concerns revolve around whether UNH's earnings have genuinely reset, requiring Medical Loss Ratio-driven upside rather than just cost controls; the impact of the October 2027 Star ratings on Medicare Advantage quality bonuses, which could delay margin recovery; and the potential for a new coding adjustment in the February 2026 Medicare Advantage rate update, similar to a prior adjustment that reduced revenue by $16 billion. Analysts warn that an unfavorable outcome in any of these areas could keep the stock, already down nearly 39% year-to-date, in limbo for another 12 months.

Analysis

Bank of America maintains a 'Neutral' rating on UnitedHealth Group (UNH), asserting that a new investment from Berkshire Hathaway is insufficient to resolve three critical near-term uncertainties. Despite raising its price objective to $325 from $290 on stronger peer multiples, the bank's analysis highlights significant hurdles to the stock's recovery. The first concern is the quality of earnings, as UnitedHealth's revised 2025 guidance of $16 per share needs to be followed by beats driven by core performance improvements in the Medical Loss Ratio (MLR), not just cost controls which have characterized results for the past two years. The second major risk is the upcoming release of 2027 Medicare Advantage Star ratings in October; a meaningful decline could defer a return to normalized margins until 2028 at the earliest, with analysts noting that recent operational challenges suggest a negative surprise is possible. Finally, the February 2026 update on 2027 Medicare Advantage rates could introduce a new adverse coding adjustment, a risk underscored by the prior V28 adjustment which reduced UNH's revenue by an estimated $16 billion. With the stock already down nearly 39% year-to-date, an unfavorable outcome on any of these three fronts could result in another 12 months of underperformance.

Key Decisions for Investors

• Investors should exercise caution as the 'Neutral' rating and multiple unresolved issues suggest the stock may remain stagnant for at least another year pending further clarity.
• Monitor three key catalysts for directional signals: the quality of earnings reports with a focus on Medical Loss Ratio improvements, the October release of 2027 Medicare Advantage Star ratings, and the February 2026 Medicare Advantage rate update.
• While Berkshire Hathaway's stake signals potential long-term value, the significant near-term regulatory and execution risks must be weighed, as a negative outcome in any of the identified areas could invalidate the bullish thesis and extend underperformance.